

**REMARKS**


Claims 3, 4, and 22 to 24 are now in the case. Claims 1, 2, 5 to 21, and 25 to 37 have been canceled. No claims have been added or amended.

The Applicants hereby elect Group VI, Claims 3, 4, and 14 to 24. Of the claims remaining in the case, Claims 3, 4, and 22 to 24 read on the elected subject matter. The Applicants further elect as the species-for-search purposes the sequence of the TACI/BCMA extracellular consensus sequence (SEQ ID NO: 13).

The Applicants have made the foregoing election and amendment in response to the restriction requirement and in the interest of compact prosecution. The Applicants reserve the right to file divisional applications on any or all of the claims canceled hereby.

In light of the foregoing amendments and remarks, the Applicants respectfully request entry of all amendments and allowance of all claims.

Respectfully submitted,



Timothy J. Gaul  
Attorney for Applicants  
Registration No.: 33,111  
Phone: (805) 447-2688  
Date: May 2, 2002

Please send all future correspondence to:  
U.S. Patent Operations/ TJG  
Dept. 4300, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799

VERSION WITH MARKINGS TO SHOW CHANGE

At page 11, line 15:

Figure 21 shows the sequence of Fc linked human APRIL (SEQ ID NO: 31).